预约演示
更新于：2025-10-09
Phytonadione
维生素K1
更新于：2025-10-09
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1955-09-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C31H46O2 |
InChIKeyMBWXNTAXLNYFJB-NKFFZRIASA-N |
CAS号84-80-0 |
关联
168
项与 维生素K1 相关的临床试验CTR20252350
维生素K1注射液人体生物等效性研究（口服给药）
CTR20251738
健康成年参与者空腹状态下口服维生素K1注射液的单中心、随机、开放、单剂量、两周期、两序列、交叉生物等效性试验
NCT06385275
The Role of Vitamin K on Knee Osteoarthritis Outcomes
100 项与 维生素K1 相关的临床结果
登录后查看更多信息
100 项与 维生素K1 相关的转化医学
登录后查看更多信息
100 项与 维生素K1 相关的专利（医药）
登录后查看更多信息
10,357
项与 维生素K1 相关的文献（医药）2025-12-31RENAL FAILURE
Triptolide improves microbial dysbiosis and metabolite disorder in db/db mice
Article
作者: Lu, Lingfei ; Chen, Jiwei ; Lu, Jiandong ; Sun, Linlin ; Liu, Fang ; Peng, Hongcheng ; Xiong, Guoliang ; Zhuang, Jiamei ; Zhou, Yanyan ; Fu, Tian ; Li, Yixin
BACKGROUND:
Diabetic kidney disease (DKD) is an increasing global public health problem. Triptolide (TP) has a good therapeutic effect on DKD and is widely used in China. However, the mechanism of TP is still unclear.
METHODS:
Db/db mice models were subjected to TP for 12 weeks. UHPLC-QE-MS and 16S rRNA amplicon sequencing were used to investigate the correlations between the metabolome, microbiome, and DKD-related indicators under DKD condition.
RESULTS:
TP demonstrated significant nephroprotective effects in db/db mice, ameliorated renal functional impairment and structural damage while attenuated inflammatory responses associated with DKD. Notably, TP administration effectively restored gut microbiota dysbiosis in db/db mice. Comparative analysis identified ten altered microbial taxa across groups, including Bifidobacterium, Erysipelotrichaceae_U-CG003, Herminiimonas, Domibacillus, Methylobacterium-Methylorubrum, Phascolarctobacterium, Dorea, Ralstonia, UCG-002, and Dubosiella, suggesting their potential utility as discriminative biomarkers for DKD progression and therapeutic response. Metabolomic profiling revealed 11 significantly perturbed metabolites, with small molecule pathway database (SMPDB) enrichment analysis highlighting three critical metabolic pathways: vitamin K metabolism, propionate metabolism, and steroid biosynthesis. Mechanistic investigations suggest that TP may reduce the inflammatory response through the JNK/STAT/P53 pathway, regulate the changes of intestinal flora, and correct renal metabolic disorders to exert renal protection.
CONCLUSION:
TP may play a renal protective role by regulating the changes of intestinal microflora and correcting renal metabolic disorders, which may be related to the JNK/STAT/P53 pathway involved in reducing the inflammatory response. In addition, Vitamin K2 has a synergistic anti-inflammatory effect with TP.
2025-12-31Journal of the International Society of Sports Nutrition
Comparison of cheese with and without
Propionibacterium freudenreichii
subsp.
shermanii
LMGT 2951 on off-season muscle strength and VO
2
max development in Nordic skiers: a randomized clinical trial
Article
作者: Larsen, Stig ; Mathisen, Therese Fostervold ; Sundgot-Borgen, Jorunn ; Lundberg, Helge Einar
BACKGROUND AND OBJECTIVE:
Nordic skiers represent a low-impact, weight-sensitive sport and may be inclined to engage in weight-controlling behavior, hence increasing their risk for low energy availability and impairment in health and performance. Jarlsberg cheese (J) is rich in vitamin K₂ from fermentation by Propionibacterium freudenreichii subsp. shermanii LMGT 2951 (Pf) and lactic acid bacteria and increases the osteocalcin (OC) level. Vitamin K is essential for activating OC, which is described to be associated positively with muscle strength, whereas propionic acid bacteria are found to enhance endurance. Except for Pf and its by-products, J and Norvegia (N) cheeses have almost identical nutrient content. The objective of this study was to compare the effects of Jarlsberg and N as potential supplements to training on muscle strength (MS), lean body mass (LBM) and VO2 max.
METHODS:
Thirty female and 30 male Nordic skiers were block randomized 1:1 to either J or N and studied during a 24-week offseason training schedule. The Norvegia group served as a control group. Females and males were treated with 75 and 90 grams/day, respectively. MS by seated pulldown and half-squat, LBM by DXA, and VO2 max were measured at baseline and after the 24 weeks off-season period. Dietary intake and training hours were registered and monitored at baseline and every eight weeks during the study.
RESULTS:
MS significantly increased in both groups after 24 weeks (p < 0.01). The mean increase difference in MS-upper body favored Jarlsberg by 0.95 kg (95% CI: -0.02-1.46), approaching significance (p = 0.06). No significant difference was found between groups in MS-lower body. LBM and VO2-max both increased significantly in each group (p ≤ 0.05), with no notable differences between groups. Correlation analysis identified LBM as the dominant outcome variable at both baseline and 24 weeks. Endurance training was the dominant input variable and correlated significantly positively both multiply and partially to LBM, (p = 0.04, p = 0.02), respectively. At baseline and 24-weeks sex, endurance training along with OC-level explained 65% and 68% of the LBM variations, respectively.
CONCLUSION:
Both Jarlsberg cheese, characterized by its unique Propionibacterium freudenreichii content, and Norvegia cheese, when combined with off-season training, led to increases in LBM, VO₂ max, and MS, with no significant differences observed between groups. However, there was a trend toward greater improvements in MS in the Jarlsberg group. Overall, increases in LBM through structured training appear to be a key driver of gains in both muscle strength and aerobic capacity.
PROTOCOL NUMBER:
XCS-Jarlsberg/IIA.
CLINICALTRIAL.GOV:
NCT06688032.
2025-12-31ANNALS OF MEDICINE
The role of fat-soluble vitamins on bone metabolism and osteoporosis: a literature review
Review
作者: Cao, Wenhai ; Zhu, Yue ; Li, Hongyang ; Tao, Lin
PURPOSE:
The purpose of this review is to discuss the role of fat-soluble vitamins in bone metabolism and explore whether there is a relationship between each fat-soluble vitamins in the occurrence and development of osteoporosis.
METHODS:
We selected several databases, including PubMed, PubMed Central (PMC), Embase, and Web of Science, as the primary sources for the search. Keywords closely related to the subject of this study, such as 'osteoporosis', 'vitamin A', 'vitamin D', 'vitamin E', 'Vitamin K', 'ferroptosis', 'osteoblast' and 'osteoclast', were used in the search. The search deadline is April 20, 2025. All included clinical studies were graded for critical analysis GRADE.
RESULTS:
Among 573 reviewed articles, 182 were included (52 met GRADE criteria: A=10, B=26, C=11, D=5; 130 N/A). Vitamins D and K enhance osteoblast differentiation via RUNX2/ALP upregulation. Vitamin A's bone effects remain debated, potentially interacting with vitamin D. Vitamins E and K may jointly regulate bone metabolism as ferroptosis inhibitors.
CONCLUSION:
i Fat-soluble vitamins (D, K, E) may positively impact bone mineral density (BMD), while vitamin A's effects remain controversial, potentially harming BMD at high doses. Current single-vitamin studies have limitations; future research should explore combined vitamin interactions to advance osteoporosis diagnosis and treatment.
100 项与 维生素K1 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 维生素K缺乏症 | 日本 | 1962-03-31 | |
| 低凝血酶原血症 | 美国 | 1955-09-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 凝血障碍 | 申请上市 | 加拿大 | 2021-06-17 | |
| 骨质疏松症 | 临床3期 | 美国 | 2000-09-01 | |
| 维生素K缺乏性出血 | 临床1期 | 中国 | 2023-07-28 | |
| 皮疹 | 临床前 | 意大利 | 2011-05-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 59 | 築獵醖構衊窪夢獵醖積(選簾壓糧願襯壓淵簾夢) = 願鬱構繭蓋鑰製壓製製 蓋艱膚醖觸製積遞窪顧 (廠餘鑰淵餘繭衊遞鏇積, 0.6) 更多 | - | 2016-05-30 | |||
N/A | - | Vitamin K1 supplement | 製襯鹹構襯製糧襯積糧(齋構廠築衊糧簾鏇選範) = 憲觸夢觸廠觸艱願衊壓 蓋襯獵鏇積餘窪願顧鬱 (繭繭製獵範鑰衊鹽築製 ) 更多 | - | 2015-08-01 | ||
(Placebo) | 製襯鹹構襯製糧襯積糧(齋構廠築衊糧簾鏇選範) = 憲蓋齋網壓選繭構憲鏇 蓋襯獵鏇積餘窪願顧鬱 (繭繭製獵範鑰衊鹽築製 ) 更多 | ||||||
N/A | 16 | 夢範鏇製夢夢蓋壓構遞(廠簾網窪夢鏇積觸選簾) = 範壓構蓋網淵製襯窪製 鹹簾獵衊壓鏇構壓窪憲 (願壓淵積鑰網簾鹽選膚, 0.68) 更多 | - | 2012-12-04 | |||
临床3期 | - | 獵鹹遞膚積鹹蓋淵餘鏇(鏇製構範觸觸餘鑰膚網) = 糧築鬱齋鬱製廠廠鏇顧 獵齋蓋選繭鏇顧廠齋築 (願淵遞顧鑰餘選構簾壓 ) | - | 2010-12-01 | |||
Placebo | 獵鹹遞膚積鹹蓋淵餘鏇(鏇製構範觸觸餘鑰膚網) = 鏇齋襯遞遞衊網願廠淵 獵齋蓋選繭鏇顧廠齋築 (願淵遞顧鑰餘選構簾壓 ) | ||||||
N/A | 120 | 廠鹽遞築艱鬱壓廠醖窪(製窪範襯簾窪選構網憲) = 襯鹹蓋襯網簾衊網鹹願 餘築觸艱觸繭廠願築鹽 (衊築淵積餘廠獵衊壓憲 ) | - | 2010-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用